Ignite Creation Date:
2024-05-06 @ 7:31 AM
Last Modification Date:
2024-10-26 @ 11:49 AM
Study NCT ID:
NCT02558231
Status:
COMPLETED
Last Update Posted:
2021-04-13
First Post:
2015-09-22
Brief Title:
The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
Sponsor:
Actelion
Organization:
Actelion
Study Overview
Official Title:
The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension A Multi-center Double-blind Placebo-controlled Phase 3b Study
Status:
COMPLETED
Status Verified Date:
2021-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TRITON
Brief Summary:
The objective of this clinical trial is to compare the efficacy and safety of an initial triple oral treatment regimen macitentan tadalafil selexipag versus an initial dual oral treatment regimen macitentan tadalafil placebo in newly diagnosed treatment-naïve patients with pulmonary arterial hypertension
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None